Yale University, 333 Cedar St, LLCI-101, New Haven, CT 06520-8020, USA.
Diab Vasc Dis Res. 2012 Apr;9(2):109-16. doi: 10.1177/1479164111436236. Epub 2012 Feb 15.
Type 2 Diabetes continues to rise in prevalence throughout the globe, and cardiovascular diseases remain the most common cause of morbidity and mortality among patients. Dipeptidyl-peptidase-4 (DPP-4) inhibitors are a newer class of oral anti-hyperglycemic agents whose effect is mediated through the incretin hormones, GLP-1 and GIP. In this review, we discuss the incretin system, DPP-4 inhibitors and their mechanism of action and, principally, the potential impact of DPP-4 inhibition on the cardiovascular system. Some pre-clinical data, small mechanistic studies and post-hoc analyses of randomized clinical trials suggest a possible beneficial effect on cardiovascular risk. However, the relationship between DPP-4 inhibition and actual cardiovascular outcomes remains unknown. We therefore also review ongoing large, randomized clinical trials examining this very question.
2 型糖尿病在全球的患病率持续上升，心血管疾病仍然是患者发病率和死亡率的最常见原因。二肽基肽酶-4（DPP-4）抑制剂是一类新型的口服抗高血糖药物，其作用通过肠促胰岛素激素 GLP-1 和 GIP 介导。在这篇综述中，我们讨论了肠促胰岛素系统、DPP-4 抑制剂及其作用机制，主要是 DPP-4 抑制对心血管系统的潜在影响。一些临床前数据、小型机制研究和随机临床试验的事后分析表明，DPP-4 抑制可能对心血管风险有有益影响。然而，DPP-4 抑制与实际心血管结局之间的关系尚不清楚。因此，我们还回顾了正在进行的大型随机临床试验，以检验这一问题。
